Stocks · News reference
The companies are collaborating to integrate Eversense® 365 CGM with Beta Bionics’ iLet® Bionic Pancreas automated insulin delivery (AID) system designed to simplify diabetes management. The integrated device will aim
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Beta Bionics reported Q3 2026 net sales of $35.5 million and updated its full-year 2026 revenue guidance to $124 million–$126 million. The company also announced the withdrawal of its 510(k) application for the 3D Intelligence algorithm to provide additional validation data.
A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels and causing hundreds of life-threatening hypoglycemic events. The company allegedly failed to disclose thousands of customer complaints to the FDA and misrepresented the scope of FDA Form 483 findings. Investors who purchased stock between July 30, 2025 and February 24, 2026 can join the lawsuit with a November 3, 2026 deadline to request lead plaintiff status.
Filed: 2026-10-27 AccNo: 0001171843-26-006856 Size: 356 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Jefferies analyst Michael Toomey initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Buy rating and announces Price Target of $30.
Sensirion has launched the SFM3304-D, a single-use gas flow sensor designed for proximal flow measurement in mechanical ventilation and respiratory applications.
Senseonics Holdings, Inc. has commenced the first-in-human clinical study for its investigational 'Freedom' continuous glucose monitoring (CGM) system, which is designed to operate without an external on-body transmitter.